RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+14.22%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$949M
AUM Growth
+$949M
(+4.1%)
Cap. Flow
-$29.1M
Cap. Flow
% of AUM
-3.06%
Top 10 Holdings %
Top 10 Hldgs %
31.29%
Holding
98
New
10
Increased
21
Reduced
41
Closed
15
Top Buys
| 1 |
Eli Lilly
LLY
|
$38M |
| 2 |
Zimmer Biomet
ZBH
|
$20.1M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$13.4M |
| 4 |
Intuitive Surgical
ISRG
|
$11.6M |
| 5 |
Procept Biorobotics
PRCT
|
$9.86M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
$21.1M |
| 2 |
Tenet Healthcare
THC
|
$9.77M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$9.44M |
| 4 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$8.61M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$8.33M |
Sector Composition
| 1 | Healthcare | 99.42% |
| 2 | Industrials | 0.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IGMS
76
DELISTED
IGM Biosciences
IGMS
| $1.85M | 0.19% |
200,000
+105,000
| +111% | +$969K |
|
77
INmune Bio
INMB
$52.4M
| $1.62M | 0.17% |
+178,284
| New | +$1.62M |
|
78
Allogene Therapeutics
ALLO
$249M
| $1.49M | 0.16% |
300,000
| – | – |
|
79
TG Therapeutics
TGTX
$5.03B
| $1.37M | 0.14% |
+55,000
| New | +$1.37M |
|
80
Mersana Therapeutics
MRSN
$34.8M
| $1.32M | 0.14% |
400,000
+50,000
| +14% | +$165K |
|
81
ESSA Pharma
EPIX
$11.2M
| $963K | 0.1% |
356,500
| – | – |
|
82
Rigel Pharmaceuticals
RIGL
$710M
| $327K | 0.03% |
253,832
-903,761
| -78% | -$1.17M |
|
|
83
Thermo Fisher Scientific
TMO
$183B
| $261K | 0.03% |
500
-40,500
| -99% | -$21.1M |
|
|
ISEE
84
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-280,000
| Closed | -$6.66M |
|
|
VRAY
85
DELISTED
ViewRay, Inc.
VRAY
| – | – |
-1,000,000
| Closed | -$3.32M |
|
|
SGEN
86
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-41,000
| Closed | -$8.33M |
|
|
SILK
87
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| – | – |
-221,255
| Closed | -$8.61M |
|
88
Stereotaxis
STXS
$246M
| – | – |
-493,618
| Closed | -$953K |
|
89
Sangamo Therapeutics
SGMO
$161M
| – | – |
-314,157
| Closed | -$534K |
|
90
Rapid Micro Biosystems
RPID
$105M
| – | – |
-127,152
| Closed | -$165K |
|
91
Insulet
PODD
$24.2B
| – | – |
-24,000
| Closed | -$7.61M |
|
92
Phreesia
PHR
$1.81B
| – | – |
-120,000
| Closed | -$3.7M |
|
93
Pfizer
PFE
$141B
| – | – |
-190,000
| Closed | -$7.67M |
|
94
NovoCure
NVCR
$1.35B
| – | – |
-45,000
| Closed | -$2.62M |
|
95
Nkarta
NKTX
$149M
| – | – |
-200,000
| Closed | -$680K |
|
96
Esperion Therapeutics
ESPR
$490M
| – | – |
-900,000
| Closed | -$1.5M |
|
97
Agilon Health
AGL
$497M
| – | – |
-90,000
| Closed | -$2.1M |
|